Latest News

Study Finds New Mutation in Ashkenazi Jews

Jewish Exponent

Basser researcher Kara N. Maxwell, MD, PhD, is the lead author of a recent study about a newly-described genetic mutation in the TP53 gene, which can increase the risk of developing multiple types of cancer. Basser genetic counselor Jacquelyn Powers, MS, LCGC, was a co-first author on the study.

Genetic Counseling for Cancer Shifts to a New Era of Virtual Care

Cure Magazine

The latest episode of the “CURE Talks Cancer” podcast features Basser genetic counselor Dana Farengo Clark discussing how genetic counseling is adjusting to the new normal and shifting into the virtual era of cancer care.

Kim Reiss Binder

When isolation is worse than death: a Philly oncologist on cancer patients and COVID-19 l Opinion

Philadelphia Inquirer

Basser researcher and Penn Medicine oncologist Kim Reiss Binder, MD, shares the difficulty of treating cancer patients during the pandemic. "As our patients have taught us, we must continue to hope for a brighter tomorrow."

Angela Bradbury

Angela R. Bradbury, MD, on Telemedicine in Genetic Counseling

Cancer Network

Cancer Network interviewed the Basser Center's Angela R. Bradbury, MD, about Penn’s efforts to continue genetic counseling during the COVID-19 pandemic.

EMBRACA Trial Shows No Overall Survival Difference Between Talzenna, Chemotherapy Arms

Precision Oncology News

Basser Executive Director Susan Domchek, MD, is quoted in this discussion of the EMBRACA trial, which examined the PARP inhibitor talazoparib and its impact on BRCA-related breast cancer treatment.

Harvey Parker and family

Genetic Testing Leads Me to a PARP Inhibitor Trial

Let's Win! Pancreatic Cancer

Harvey Parker generously shares the story of his pancreatic cancer treatment and his participation in a Basser Center and Penn Medicine clinical trial run by Dr. Kim Reiss Binder.

Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer

Journal of the American Medical Association

Basser scientists were part of this Penn Medicine team effort studying PARP-1 expression and breast cancer.

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

Journal of Clinical Oncology

Basser Executive Director Susan Domchek, MD, and Basser Director of Genetics Katherine L. Nathanson, MD, were involved in this study to examine the risk of various cancers associated with the PALB2 genetic mutation.

DNA strand

PARP inhibitor drugs can be ‘tuned’ for better killing of tumor cells

Penn Today

Using innovative techniques, a new Penn Medicine study helps clear up mystery about why PARP-inhibiting compounds vary so much in their clinical effectiveness.

Structural basis for allosteric PARP-1 retention on DNA breaks


Ben Black, PhD, a professor at Penn Medicine and Basser funded scientist, recently published a paper exploring the mechanisms of PARP binding, which looks to explain the difference in efficiency of the various PARP inhibitor cancer treatments. 

DNA Repair Enzyme

PARP inhibitor drugs can be ‘tuned’ for better killing of tumor cells

Penn Today

Using innovative techniques, a new Penn Medicine study helps clear up mystery about why PARP-inhibiting compounds vary so much in their clinical effectiveness.

Allison Werner-Lin

Working on ‘the human side’ of heritable cancers

Penn Today

How do you make major life decisions knowing you are likely to develop cancer? Allison Werner-Lin looks at these questions, studying the intersection of genetics and family life.

Kim Reiss Binder

Penn is fighting pancreatic cancer

Penn Today

Researchers within the Penn Pancreatic Cancer Research Center and beyond continue to seek innovative ways to treat and detect this deadly disease—and are making promising progress.


The Other Jewish Women’s Cancer

Lilith Magazine

Lilith Magazine examined the genetic risk of ovarian cancer, especially in Jewish women, and interviewed Basser Executive Director Susan Domchek, MD, about prevention, screening, and treatment options.

National BRCA Study Sees Lower Participation in Philly

Jewish Exponent

The Jewish Exponent highlights the BFOR Study, which offers no-cost testing to men and women of Ashkenazi Jewish descent for BRCA gene mutations. Basser Executive Director Susan Domchek, MD, a principal investigator on the study, notes that the Philadelphia area is still open for enrollment.

Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer


This paper in Genetics in Medicine is a collaborative effort between Penn Medicine, the Basser Center, and researchers across the country. It is the first large-scale report on the CTNNA1 gene, which may represent a risk factor for early-onset gastric cancer and possibly breast cancer.

Domchek interview

As Home Genetic Tests Flood Market, Are Physicians Being Left Behind?


Susan Domchek, MD, Executive Director of the Basser Center, discussed at-home genetic testing and whether or not patients who need these tests the most have access.

The Reinterpretation of Genetic Tests Is Rare

Wall Street Journal

In a letter to the editor in the Wall Street Journal, Basser’s Kara Maxwell, MD, PhD, and Susan Domchek, MD, responded to an article the paper recently published about genetic testing, pointing out that reinterpretation of a patient’s genetic testing results is an incredibly rare case.